Summary of CONMED's Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Sales: Approximately $338 million, reflecting a 6.7% year-over-year growth (6.3% in constant currency).

Adjusted Net Income: $33.4 million, up 2.2% year-over-year.

Adjusted Diluted EPS: $1.08, an increase of 2.9% compared to the prior year.

Adjusted Gross Margin: 56.1%, slightly below the previous year due to manufacturing variances and tariffs.

Cash Flow from Operations: $53.7 million, compared to $51.2 million in Q3 2024.

Long-term Debt: Reduced to $853 million from $881 million in the previous quarter.

2Strategic Updates and Business Highlights

Growth Drivers: Key platforms include BioBrace and AirSeal, with BioBrace expanding its applications to over 70 procedures, indicating strong clinical adoption.

General Surgery Performance: Notable growth from Buffalo Filter and AirSeal, driven by legislative mandates and clinical benefits.

Portfolio Review: A comprehensive strategic review is underway to sharpen focus on core markets and improve margins.

Capital Allocation Shift: The company suspended its dividend in favor of a $150 million share repurchase program to enhance financial flexibility and align with peers.

3Forward Guidance and Outlook

Q4 Revenue Guidance: Expected between $363 million and $370 million, indicating mid-single-digit constant currency growth.

Full Year 2025 Revenue Guidance: Narrowed to $1.365 billion to $1.372 billion.

Adjusted EPS Guidance for Q4: Projected between $1.30 and $1.35, with full-year adjusted EPS guidance at $4.48 to $4.53.

4Bad News, Challenges, or Points of Concern

Tariff Impact: Continued headwinds from tariffs are expected to affect margins, with $0.07 impact projected for Q4.

Supply Chain Issues: Ongoing challenges in recapturing market share due to previous supply chain disruptions, with expectations for gradual recovery.

GAAP Net Income Decline: Reported GAAP net income was $2.9 million, a significant drop from $49 million in the prior year, highlighting discrepancies between adjusted and GAAP results.

5Notable Q&A Insights

Capital Allocation Strategy: Management clarified that suspending the dividend was a strategic move to prioritize share repurchases after achieving a leverage ratio of 3.0x.

Supply Chain Recovery: Progress is being made, but management cautioned that full recovery may take additional quarters.

AirSeal Adoption: Questions about the adoption rates for AirSeal in non-robotic laparoscopic procedures and international markets were addressed, indicating ongoing opportunities.

Market Share Recovery: Management anticipates a gradual process for regaining market share as supply issues resolve, rather than an immediate rebound. Overall, CONMED demonstrated solid growth in Q3 2025, with strategic initiatives aimed at enhancing long-term profitability, despite facing challenges related to tariffs and supply chain disruptions.